Whole PVA focus is on increasing production.
Dividend would be counterproductive -- actually downright dumb.
Keep your eye on the ball.
So Soros buys a bunch of PVA shares and then demands that the company sell itsel so that he can double his money.
If he was a truly "legendary" investor he would try to broker a deal that would serve everyone's interests. I think one potential favorable outcome would be to entice a major player to make a bid for PVA with the understanding that current PVA management would be in charge of a new shale E+P division for the major -- for which which PVA has proven to be a very good operator.
Until he does more than complain and demand, Soros is not showing us much.
The "old" options will be a combination of NE and PGN -- if you are called you will have to give up both stocks.
The "new" options will be separate for NE and PGN. You will be ab;e to buy or write options on the separate companies.
I sold covered calls on "Old" NE -- so I have keep both stocks until the options expire or I am called.
The PVA investor relations contact (Jim Dean) is very responsive to questions from shareholders.
I think PVA is know for keeping tight chokes on their wells, as opposed to EOG, which seems to take delight in reporting "monster" IPs.
Very good points.
Even if the contract is poorly written from the standpoint of LQDT, they can win compensation on the basis of fairness.
The general spirit of the law takes precedence and comes down on the side of fairness to all parties.
I'm not a lawyer but contracts are considered sacred.
If LQDT did not agree to this type of stoppage in the original contract wording, they will get paid for the loss. You can book it. (They have a strong equity claim to recoup losses at worst)
From what I have read here, LQDT agreed to a "request" from the DLA -- not an arbitrary order to stop the auctions.
If LQDT is going along with DLA, there has to be something in it for LQDT.
Stopping a contractual agreement that causes financial loss to one of the partners calls for a settlement to make good the loss. Unless DLA has reserved the right to do this, LQDT could be in for a nice payday down the line.
There is more to this than initially meets the eye.
LQDT is going along with this because they might have a shot at getting this thing re-bid.
There is always shorting of the common when a convert is issued.
To the posters who don't like actions of the current management, I would only remind you that it was this management that took the risk and went all in on the Eagle Ford. Maybe you would look more kindly on management if you had recognized the potential of what they were doing and bought the stock in the 4s, like some of us did.
If I had accomplished what this management team has accomplished I would also want to be rewarded.
What did Soros do but wait until the production was skyrocketing and then make demands on management -- throwing his weight around.
When I look back at the moves this management has made in the last few years I don't see many missteps.
Gene therapy moving ahead at breakneck speed -- won't be that long until cures are here.
David Guyer, CEO of OPHT, just came on the board of AGTC this am.
OPHT, REGN telling you where the future lies.
AGTC now has alliance with Sigma-Aldrich to make AAV gene therapy more available to the research community.
People want to invest in disruptive technologies -- not primitive stopgaps.
Something like shale, maybe, but not exactly shale.
(Your question exceeds my level of knowledge of jurassic sedimentary formations)
REGN -- which has by far the best science — has made an important partnership with Avalanche and is now looking at CURES for retinal diseases. Therapies that treat retinal diseases as chronic are soon going to be yesterday's news. Look at a company like AGTC, which I believe has never even been mentioned here.
Retinal diseases are among the most genetically related of all human diseases. As REGN and AGTC have now indicated, gene replacement will be the real long-term CURE for retinal diseases. Everything else will be interim therapy if you are seeking a longer-term perspective.
The most knowledgeable venture capitalists are only interested in CURES at this point. So place your bets carefully of you might be backing a dying horse.
I started wondering about Livermore when he started to go on the REGN message board warning REGN shareholders that they were doomed. Seemed a bit much for a professional guy.